D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend’s Angiogenesis, Exudation, and ...

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research ...

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found.

H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant volatility, with ...

Engineering students like An Le (left) and Bo Wen (center) work with Professor Truong Nguyen (right) to develop AI tools that ...

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...